

Attorney Docket No.: 6207.520 -US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pingel et al.

Conf. No.: 3225

Application No.: 10/725,843

Group Art Unit: 1652

Filed: December 2, 2003

Examiner: Swope, Sheridan Lee

For: Method for Producing Factor VII Glycoforms

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby submit 3 sheets listing references and other information for consideration by the Examiner in accordance with 37 C.F.R. 1.56, 1.97, and 1.98:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No.	10/725,843
				Filing Date	December 2, 2003
				Applicant	Pingel et al.
				Art Unit	1652
				Examiner Name:	Swope, Sheridan Lee
Sheet	1	of	3	Atty. Docket No.	6207.520 -US

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number-Kind Code ^(if known)	Issue/Publication Date MM-DD-YYYY	NAME of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		5,015,576	05-14-1991	Nilsson, K et al.	
		6,458,565	10-01-2002	Cunningham, M. et al.	
		4,357,422	11-02-1982	Giard, D. et al.	
		4,335,215	06-15-1982	Heeres, J. et al.	
		5,654,197	08-05-1997	Jem, K-M., et al.	
		4,189,534	02-19-1980	Levine, D. et al.	
		5,576,194	11-19-1996	Chan, Sham Y.	
		5,661,008	08-26-1997	Almsteadt, A.B. et al.	
		4,978,616	12-18-1990	Dean, R.C. et al.	
		6,475,725	11-05-2002	Reiter, M. et al.	
		6,936,441	08-30-2005	Reiter, M. et al.	
		4,664,912	05-12-1987	Wiktor, T. et al.	
		5,510,328	04-23-1996	Polarek, J. et al.	
		4784,950	11-15-1988	Hagen, F.S. et al.	
		2002/0099191	07-25-2002	Kostenis, E. et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number-Kind Code ^(if known)	Publication Date MM-DD-YYYY	NAME of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T
		WO 02/29083	04-11-2002	Novo Nordisk A/S		
		WO 02/29084	04-11-2002	Novo Nordisk A/S		
		WO 95/13361	05-18-1995	Genzyme Corp.		
		WO 93/22448	11-11-1993	Teijin Ltd.		
		WO 93/22425	11-11-1993	Novo Nordisk A/S		
		WO 98/04680	02-05-1998	Univ. of Manitoba		
		EP 0212880	04-03-1987	The Isreal Institute for Biological Research		
		EP 1115678	07-18-2001	Franzen, Bo		

EXAMINER SIGNATURE		DATE CONSIDERED	
-----------------------	--	--------------------	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No.	10/725,843
				Filing Date	December 2, 2003
				Applicant	Pingel et al.
				Art Unit	1652
				Examiner Name:	Swope, Sheridan Lee
Sheet	2	of	3	Atty. Docket No.	6207.520 -US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T
		WAGNER, A. et al., Continuous Production of Prourokinase in feed Harvest and Perfusion Cultures, Biotechnology and Bioengineering, Vol. 36(6), pp. 623-9 (1990)	
		KENNARD, M.L. et al., Membrane Achored Protein Production from Sphero, Porous and Solid Microcarrier Chines Hamster Ovary Cell Cultures, Biotechnology and Bioengineering, Vol. 47(5), pp. 550-6 (1995)	
		SUNDERJI, R. et al., Increasing GPI-Anchored Protein Harvest Concentrations from Suspension and Porous Microcarrier CHO Cell Cultures, Biotechnology and Bioengineering, Vol. 55(1), pp. 136-47 (1997)	
		SINACORE, M.S. et al., CHO DUKX Cell Lineages Preadapted to Growth in Serum-Free Suspension Culture Enable Rapid Development of Cell Culture Processes for the Manufacture of Recombinant Proteins, Biotechnology and Bioengineering, Vol. 52(4), pp. 518-28 (1996)	
		PERSSON, E. et al., Substitution of Aspartic Acid for Methionine-306 in Factor VIIa Abolishes the Allosteric Linkage between the Active Site and the binding Interface with Tissue Factor, Biochemistry, Vol. 40(11), pp. 3251-6 (2001)	
		PERSSON, E. et al., Substitution of Valine for Leucine 305 in Factor VIIa Increases the Intrinsic Enzymatic Activity, Journal of Biological Chemistry, Vol. 276(31), pp. 29195-9 (2001)	
		WEN, ZHI-YOU et al., A novel perfusion system for animal cell cultures by two step sequential sedimentation, Journal of Biotechnology., Vol. 79, pg. 11 (2000)	
		GRIFFITHS, J.B., Animal cell culture processes – batch or continuous?, Journal of Biotechnology, Vol. 22(1), pp. 21-30 (1992)	
		XIE, LIANGZHI and DANIEL, I.C.V., Integrated approaches to the design of media and feeding strategies for fed-batch cultures of animal cells, Trends in Biotechnology, Vol. 15(3), pp. 109-13 (1997)	
		ZANG, M. et al., Production of Recombinant Proteins in Chinese Hamsetr Ovary Cells Using A Protein-Free Cell Culture Medium, Bio/Tech, Vol. 13, pp. 389-92 (1995)	
		TOMOKIYO, K. et al., Large-scale production and properties of human plasma-derived activated Factor VII concentrate, Vox Sanguinis, Vol. 84, pp. 54-64 (2003)	
		NOMURA, N. et al., Improved MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) Assay For The Measurement of Viable Animal Cell Number In Porous Cellulose Carriers, Biotech Techniques, Vol. 10(11), pp. 883-8 (1996)	
		HU, X. et al., Pilot Production of u-PA with porous microcarrier cell culture, Cytotechnology, Vol. 33, pp. 13-9 (2000)	
		XIAO, C. et al., High Density and scale-up cultivation of recombinant CHO cell line and hybridomas with porous microcarrier Cytopore, Cytotechnology, Vol. 30, pp. 143-7 (1999)	
		European Patent Office Office Action of January 13, 2005 for Application No. 01971734.7	
		European Patent Office Office Action of April 27, 2006 for Application No. 01971734.7	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No.	10/725,843
				Filing Date	December 2, 2003
				Applicant	Pingel et al.
				Art Unit	1652
				Examiner Name:	Swope, Sheridan Lee
Sheet	3	of	3	Atty. Docket No.	6207.520 -US

NON PATENT LITERATURE DOCUMENTS

		European Patent Office Office Action of November 13, 2006 for Application No. 01971734.7	
		European Patent Office Office Action of August 29, 2007 for Application No. 01971734.7	
		European Patent Office Observations by a Third Party concerning the patentability of the invention of Application No. 01971734.7 December 12, 2006	

EXAMINER SIGNATURE		DATE CONSIDERED	
-----------------------	--	--------------------	--

Except for US patent documents, a copy of each listed reference is enclosed or submitted herewith.

Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This Information Disclosure Statement is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicants respectfully request that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: April 4, 2008

_____/Reza Green, Reg. No. 38,475/_____
Reza Green, Reg. No. 38,475
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE